GRI BIO, Inc. (GRI)
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
Address
2223 AVENIDA DE LA PLAYA
LA JOLLA, CA 92037
Founded
2009
Number of Employees
4
Website
http://www.gribio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)